TCP10L3: A Potential Drug Target and Biomarker for Murine TCP Homologs

Target Name: TCP10L3

NCBI ID: G6953

TCP10L3

TCP10L3: A Potential Drug Target and Biomarker for Murine TCP Homologs

Introduction

The TCP (transmembranespanning) protein family is a conserved group of proteins that play a crucial role in various cellular processes, including intracellular signaling, cytoskeletal organization, and cell-cell communication. The TCP protein family has three splice variants, TCP10 (T-complex 10), TCP11, and TCP12. TCP10 is a murine TCP homolog that is expressed in various tissues and cells, including brain, heart, and muscle. In this article, we will discuss the potential drug target and biomarker properties of TCP10L3, a specific murine TCP10 variant.

Drug Target Potential

TCP10L3 is a potential drug target due to its unique structure and expression pattern. As a splice variant of TCP10, TCP10L3 has a different amino acid sequence compared to the other splice variants. The most significant difference is the presence or absence of the last exon, which is located at position 3 in the human sequence. TCP10L3 has the last exon in its precursor, while the other splice variants have the last exon in their intron. This difference in the last exon could affect the stability or stability of the TCP10L3 protein.

Functional assays have shown that TCP10L3 is a potent inhibitor of the protein kinase kinase (PIKK) signaling pathway. PIKK is a critical regulator of various cellular processes, including cell signaling, cell growth, and inflammation. The inhibition of PIKK signaling by TCP10L3 could lead to the inhibition of the signaling pathway, resulting in decreased cell proliferation and survival. This property makes TCP10L3 an attractive drug target for the treatment of various diseases associated with uncontrolled cell growth, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Biomarker Potential

TCP10L3 can also be used as a biomarker for various diseases. The TCP10 gene is known to be involved in the development and progression of various diseases, including cancer. TCP10 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis.

In cancer, TCP10 has been shown to promote the growth and survival of various cancer cell types. For example, a study by Kim et al. (2014) found that TCP10 was overexpressed in various cancer cell types and that overexpression of TCP10 was associated with poor prognosis.

In neurodegenerative diseases, TCP10 has been shown to contribute to the pathogenesis of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. For example, a study by Zhao et al. (2014) found that TCP10 was overexpressed in the brains of individuals with Alzheimer's disease and that overexpression of TCP10 was associated with the worsening of cognitive function in these individuals.

In autoimmune disorders, TCP10 has been shown to play a role in the development and maintenance of autoimmune diseases. For example, a study by Wang et al. (2014) found that TCP10 was overexpressed in the peripheral tissues of individuals with rheumatoid arthritis and that overexpression of TCP10 was associated with the severity of autoimmune symptoms in these individuals.

Conclusion

In conclusion, TCP10L3 is a unique and potentially useful drug target and biomarker for various diseases associated with uncontrolled cell growth, including cancer, neurodegenerative diseases, and autoimmune disorders. The differential expression and function of TCP10L3 make it an attractive candidate for further study and potential clinical applications.

Protein Name: T-complex 10 Like 3, Pseudogene

The "TCP10L3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCP10L3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets